Pitt | Swanson Engineering

The Department of Bioengineering combines hands-on experience with the solid fundamentals that students need to advance themselves in research, medicine, and industry. The Department has a long-standing and unique relationship with the University of Pittsburgh Medical Center and other academic departments at the University of Pittsburgh as well as neighboring Carnegie Mellon University. Our faculty are shared with these organizations, offering our graduate and undergraduate students access to state-of-the-art facilities and a wide array of research opportunities. We currently have 190 graduate students who are advised by some 100 different faculty advisers, pursuing graduate research across 17 Departments and five Schools. Our undergraduate class-size of approximately 50 students per year ensures close student-faculty interactions in the classroom and the laboratory.

The main engineering building is located next to the Medical Center in Oakland, an elegant university neighborhood with museums, parks, and great restaurants. Beautiful new facilities have also been built, a short shuttle ride from the main campus, along the Monongahela River, replacing the steel mills that once were there. Our department is growing rapidly, both in numbers of students and faculty, and in the funding and diversity of our research. The Pittsburgh bioengineering community is a vibrant and stimulating alliance of diverse components for which our department forms an essential and central connection.

May
31
2017

Musculoskeletal Transplant Foundation Awards $100,000 to BioE’s Abhijit Roy

Bioengineering

PITTSBURGH, PA (May 31, 2017) … The Musculoskeletal Transplant Foundation (MTF) has chosen Dr. Abhijit Roy, a Research Assistant Professor in the University of Pittsburgh Department of Bioengineering, as a recipient of its Junior Investigator Award to help fund his research into a novel bone grafts with the potential for complete bone generation in areas with defects.“The grant is aimed at providing a revolutionary concept representing a paradigm shift in the arena of degradable materials for craniomaxillofacial bone regeneration,” said Dr. Roy. “Success of this project will establish a revolutionary technology possessing unique benefits not proffered by existing synthetic bone grafts, including complete resorption, osteoconductivity, mechanical stability throughout the complete bone healing process, and biocompatibility and safety.” Beginning in July 2017, Dr. Roy will receive $100,000 over one year for his study “Novel Mg Alloy Based Biodegradable Porous Scaffolds for Bone Regeneration of Critical Sized Cranial Bone Defects.” The research will be carried out in the group of Dr. Prashant N. Kumta, the Edward R. Weidlein Chair Professor in the Swanson School of Engineering and School of Dental Medicine. Dr. Kumta will serve as coinvestigator on the study along with Dr. Vijay S. Gorantla, assistant professor of plastic surgery at Pitt, and Dr. MaCalus V. Hogan, assistant professor of orthopaedic surgery at Pitt.The MTF Junior Investigator Award is for researchers attempting to advance allografts, the science of transplantation, and the biological reconstruction of musculoskeletal tissues. Allografts, a type of non-synthetic graft, come from donors other than the patient. They can lead to complications from adverse immune response and the risk of disease transmission. Autografts, non-synthetic grafts taken from the patient’s own tissue, usually require a second surgical site and can increase the risk for infection, require extended operating room and recovery times, and increase healthcare expenditures. According to MTF, many doctors prefer allografts over autografts because of their availability, safety, and readiness for use. However, in both allografts and autografts, the amount of tissue that can be harvested is limited. Synthetic bone graft substitutes offer new therapy options for the treatment of bone defects without the complications associated with non-synthetic grafts. “Unfortunately, the majority of synthetic bone grafts developed to date are inert and non-degradable which lead to insufficient bone formation, poor integration to the surrounding tissue, long term complications and the need for prolonged treatment with antibiotics and immunosuppressive therapies,” explained Dr. Roy. “This project will test the use of a novel degradable magnesium metal alloy-based bone graft that will lead to complete bone regeneration in a rat calvarial [or skullcap] defect.” ###
Matt Cichowicz, Communications Writer
May
10
2017

Following two decades as Dean, Gerald Holder to return to faculty at Pitt's Swanson School of Engineering

All SSoE News, Bioengineering, Chemical & Petroleum, Civil & Environmental, Electrical & Computer, Industrial, MEMS, Diversity

PITTSBURGH (May 10, 2017) ... Marking the culmination of more than two decades of dynamic leadership, Gerald D. Holder, U.S. Steel Dean of Engineering in the University of Pittsburgh’s Swanson School of Engineering, has announced his intention to step down from his position to return to the faculty in the fall of 2018.Holder, Distinguished Service Professor of chemical engineering, has been dean of the Swanson School since 1996 and a member of its faculty since 1979.“Two words come to mind when I look back on Jerry’s incredible career as dean of our Swanson School of Engineering: tremendous growth,” said Chancellor Patrick Gallagher. “Under Jerry’s leadership, our Swanson School has seen record enrollment levels and total giving to the school has topped $250 million. “The school has also expanded academically to support new knowledge in areas like energy and sustainability — and also new partnerships, including a joint engineering program with China’s Sichuan University. And while I will certainly miss Jerry’s many contributions as dean, I am grateful that he will remain an active faculty member and continue to strengthen our Swanson School’s bright future,” Gallagher said.       “Through a focus on innovation and excellence, Dean Holder has led a transformation of the Swanson School of Engineering into a leader in engineering research and education,” said Patricia E. Beeson, provost and senior vice chancellor. Beeson added, "From the establishment of the now top-ranked Department of Bioengineering to the integrated first-year curriculum that has become a national model, the Swanson School has been a change maker. And with nearly three-quarters of the faculty hired while he has been dean, the culture of success that he has established will remain long after he steps down.” The University plans to announce the search process for his successor in the coming months. Holder’s Many Accomplishments In his 21 years as dean, Holder has overseen school growth as well as increases in research awards and philanthropic gifts. Enrollment has doubled to nearly 4,000 undergraduate and graduate students, and the number of PhDs has increased threefold. Holder also has emphasized programs to nourish diversity and engagement — for example, in 2012 the Swanson School had the highest percentage in the nation of engineering doctoral degrees awarded to women. Co-curricular programs also have prospered during Holder’s tenure. The school’s cooperative education program, which places students in paid positions in industry during their undergraduate studies, has increased to approximately 300 active employers. International education or study abroad has also become a hallmark of a Pitt engineering education, with 46 percent participation in 2015 versus a 4.6 percent national average for engineering and a 22.6 percent national average for STEM fields. The school’s annual sponsored research has tripled during Holder’s years as dean, totaling a cumulative $400 million. Alumnus John A. Swanson’s landmark $43 million naming gift came in 2007, the largest-ever gift by an individual to the University at the time.University-wide initiatives developed during Holder’s tenure as dean include the Gertrude E. and John M. Petersen Institute of NanoScience and Engineering; the Mascaro Center for Sustainable Innovation, founded with support of alumnus John C. “Jack” Mascaro; and the Center for Energy.Holder is likewise held in high regard by his peers. "As a dean of long standing, many of us refer to Dean Holder as `the Dean of deans,’ not just because of his years of service but also because of the respect that we have for his leadership, mentorship and impact on the engineering profession,” said James H. Garrett Jr., dean of the College of Engineering at Carnegie Mellon University.“He is an accomplished academician, an exceptional academic leader and a tremendous human being.” Holder, a noted expert on natural gas hydrates and author of more than 100 journal articles, earned a bachelor’s degree in chemistry from Kalamazoo College and bachelor’s, master’s and PhD degrees in chemical engineering from the University of Michigan. He was a faculty member in chemical engineering at Columbia University prior to joining the Pitt engineering faculty in 1979. He served as chair of the chemical engineering department from 1987 to 1995 before being named dean of engineering.Among many professional accomplishments, he was named an American Association for the Advancement of Science Fellow in 2003. In 2008 he was named an American Institute of Chemical Engineers Fellow and was awarded the William Metcalf Award from the Engineers’ Society of Western Pennsylvania for lifetime achievement in engineering. In 2015 he was elected chair of the American Society of Engineering Educators’ (ASEE) Engineering Deans Council, the leadership organization of engineering deans in the U.S., for a two-year term. The council has approximately 350 members, representing more than 90 percent of all U.S. engineering deans and is tasked by ASEE to advocate for engineering education, research and engagement throughout the U.S., especially among the public at large and in U.S. public policy. ###
Author: Kimberly Barlow, University Communications
Apr
25
2017

ALung Submits IDE Application to FDA Seeking Approval to Conduct Pivotal Study of the Hemolung RAS

Bioengineering

PITTSBURGH (April 25, 2017) - ALung Technologies, Inc., announced today the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to conduct a pivotal clinical study of the Hemolung Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary disease (COPD). COPD affects 30 million Americans1 and is the third leading cause of death in the United States behind cancer and heart disease.2 Acute exacerbations, defined as a sudden worsening of COPD symptoms, are a major cause of morbidity and mortality in COPD patients. For patients with severe exacerbations, high levels of carbon dioxide can result in respiratory failure and the need for intubation and mechanical ventilation as life saving measures. Unfortunately, mechanical ventilation is associated with many side effects, and in-hospital mortality remains as high as 30%. The Hemolung technology aims to avoid or reduce the need for intubation and ventilator support by directly removing carbon dioxide from the blood. ALung has been working with the FDA under the Expedited Access Pathway (EAP) program to complete pre-clinical testing and finalize its clinical study protocol. “Submission of our IDE is a significant milestone, made possible only through the hard work of our team in close collaboration with the FDA,” said Peter DeComo, Chairman and CEO of ALung. “We look forward to completing the IDE review and beginning the study later this year.” ALung’s recently announced $36 million Series C financing, led by Philips and UPMC Enterprises, will support the clinical study program. About ALung Technologies ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by Philips, UPMC Enterprises, Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures, Eagle Ventures, Riverfront Ventures, West Capital Advisors, and other individual investors. For more information about ALung and the Hemolung RAS, visit www.alung.com. This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized. ### References 1. https://www.copdfoundation.org/What-is-COPD/COPD-Facts/Statistics.aspx2. http://www.lung.org/assets/documents/research/copd-trend-report.pdf
ALung Technologies News Release
Apr
18
2017

“Rescue Stent” Wins Another Award from Society For Biomaterials

Bioengineering

MINNEAPOLIS, MN (April 18, 2017) … The “Rescue Stent,” a medical device designed at the University of Pittsburgh to help manage large vessel hemorrhaging after a chest trauma, won the Audience Award at the 3rd Society For Biomaterials (SFB) 2017 Business Plan Competition. Puneeth Shridhar, MD MS, who is pursuing second doctoral degree in Bioengineering at Pitt, presented the Rescue Stent during the SFB Annual Meeting & Exposition in Minneapolis. The audience members voted for his presentation to receive the $1,000 prize and Audience Award recognition.The SFB Business Plan Competition evaluates biomaterials-based research innovations from all over the world that have the potential to succeed in the medical device industry. Participants submit abstracts containing an information about the technology, market research and a commercialization strategy. They then present their ideas in the form of a 10-minute pitch followed by a question and answer session from judges and audience members.Dr. Shridhar was attending the conference to accept another award he won earlier this year: the Honorable Mention Student Travel Achievement (STAR) Award. The SFB Education and Professional Development Committee recognized Dr. Shridhar with the STAR Award for his outstanding student paper titled “The Rescue Stent for Non Compressible Traumatic Hemorrhage.” The paper outlined the development, design and future business strategy for the Rescue Stent.In 2016, the United States Department of Defense granted $2.5 million in funds for a four-year research collaboration between the University of Pittsburgh Swanson School of Engineering and UPMC Division of Vascular Surgery to develop the Rescue Stent. The research team is working to make the Rescue Stent the first removable, collapsible and biocompatible trauma stent to prevent internal bleeding from the aorta. The Rescue Stent will have both military and civilian applications and could greatly reduce fatalities caused by gunshot wounds, stabbings and other related torso injuries.Dr. Bryan Tillman, assistant professor of vascular surgery at the School of Medicine, serves as principal investigator on the study that received funding to develop the Rescue Stent. Joining Dr. Tillman are three engineering professors: Youngjae Chun, assistant professor in the Departments of Industrial Engineering and Bioengineering; Sung Kwon Cho, associate professor of mechanical engineering and materials science; and William Clark, professor of mechanical engineering and materials science. ###
Matt Cichowicz, Communications Writer
Apr
14
2017

BioE’s Jaeyeon Choi Awarded $45,000 to Develop New Treatment for Metastatic Melanoma

Bioengineering

PITTSBURGH, PA (April 14, 2017) … The Society of Nuclear Medicine and Molecular Imaging (SNMMI) awarded Jaeyeon Choi, a graduate student in the Department of Bioengineering at the University of Pittsburgh, a two-year, $45,000 research grant for her proposal to use targeted radionuclides in the treatment of metastatic melanoma, also known as Stage IV melanoma. Radionuclide therapy is a rapidly growing branch of nuclear medicine, according to SNMMI. The treatment uses radioactive drugs called radiopharmaceuticals to target and eliminate cancer cells, often directly and with limited damage to the surrounding healthy tissue. Researchers have already developed targeted radionuclide therapies to treat certain diseases such as prostate cancer, and organizations like SNMMI are looking to expand the treatments to a variety of other cancers. In her proposal “Improving VLA-4 targeted radio nuclide therapy for metastatic melanoma with 177Lu-labeled albumin-binding LLP2A,” Choi outlined a new method of using radionuclides to treat metastatic melanoma and a new imaging strategy to better determine how patients are responding to the therapy. “Metastatic melanoma is a highly challenging disease to treat, and treatment approaches are very limited,” said Choi. “The five-year survival rate for patients is only 15-20 percent. I think my proposal was chosen because of the critical need to improve therapies and increase the overall survival of patients with metastatic melanoma.” At the University of Pittsburgh, Choi studies radionuclide therapies and diagnostics for the treatment of human diseases under the supervision of Carolyn Anderson, co-director of the University of Pittsburgh Cancer Institute In Vivo Imaging Facility. Dr. Anderson is also a professor of radiology with a secondary appointment in the Swanson School of Engineering Department of Bioengineering. Choi’s research focuses on developing novel molecular imaging probes using radionuclides to target specific immune cells, which can be used to diagnose human inflammatory diseases such as tuberculosis. She is also working on a project developing novel targeted radionuclide therapeutics for the treatment of different types of cancers.  “The bioengineering program at Pitt has given me great opportunities to incorporate different approaches to research from multiple engineering fields including tissue engineering, biomaterials and medical imaging,” said Choi. “I think technology is improving by becoming more multidisciplinary, and Dr. Anderson has really helped me take advantage of the University’s resources while designing and executing my research projects.” The SNMMI awards the Pre-doctoral Molecular Imaging Scholar Program grant to only one recipient every two years. The research scholar must be working in an established molecular imaging lab and must be a full-time student working toward a PhD or MD in an educational institution during the award period. The objective of the grant is “to encourage the integration of imaging approaches in the research of molecular pathways of disease.” Choi began studying at the University of Pittsburgh in 2015 and is on track to receive her PhD in 2019. She would like to continue her study in radiopharmaceutical science and work in a faculty position at a research institution after graduation. ###
Matt Cichowicz, Communications Writer

Upcoming Events


back
view more

Bioengineering By The Numbers

269

Number of Undergraduate Students enrolled for the 2015-2016 Academic Year

154

Number of PhD Candidates enrolled for the 2014-2015 Academic Year

50

Number of Masters Candidates enrolled for the 2015-2016 Academic Year

 


29

Number of PhD Degrees Awarded in Spring/Summer/Fall 2014 

6

Number of MS Degrees Awarded in 2013-2014 Academic Year 

59

Number of BS Degrees Awarded in 2013-2014 Academic Year 

 


467

 Number of Faculty Publications in 2013-2014 Academic Year 

89

 Number of Graduate Publications in 2013-2014 Academic Year 

50

Number of Undergraduate Publications in 2012-2013 Academic Year